RuiYi Announces $15 Million Series B to Advance Pipeline of Therapeutic ... MarketWatch RuiYi has a pipeline of innovative monoclonal antibodies to previously untargeted G protein coupled receptors (GPCRs) for important global, therapeutic needs. The financing will support the continued development of RuiYi's lead asset, RYI-008, a novel ... San Diego's RuiYi Raises $15M for Pipeline of Biologic Therapeutics RuiYi banks $15M from A-list backers to amp up Chinese R&D |
